Everything below concerns preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
== External links == Media related to Binge eating disorder at Wikimedia Commons Pull, Charles B (January 2004). "Binge eating disorder". Current Opinion in Psychiatry. 17 (1): 43–48. doi:10.1097/00001504-200401000-00008. Binge Eating Disorder on National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
M−OH + R3SiCl → M−OSiR3 + HCl M−OH + R3SiOCH3 → M−OSiR3 + CH3OH M is typically Si, but could be many other elements. The process is assumed to follow the pathways that apply to silylation of molecular substrates, such as alcohols.
=== Cationic liposomes === Another type of lipid-nanoparticle that can be used for drug delivery to the brain is a cationic liposome. These are lipid molecules that are positively charged. One example of cationic liposomes uses bolaamphiphiles, which contain hydrophilic groups surrounding a hydrophobic chain to strengthen the boundary of the nano-vesicle containing the drug. Bolaamphiphile nano-vesicles can cross the BBB, and they allow controlled release of the drug to target sites. Lipoplexes can also be formed from cationic liposomes and DNA solutions, to yield transfection agents. Cationic liposomes cross the BBB through adsorption mediated endocytosis followed by internalization in the endosomes of the endothelial cells. By transfection of endothelial cells through the use of lipoplexes, physical alterations in the cells could be made. These physical changes could potentially improve how some nanoparticle drug-carriers cross the BBB.
== Reference terminology == The terminology of isotopic reference materials is not applied consistently across subfields of isotope geochemistry or even between individual laboratories. The terminology defined below comes from Gröening et al. (1999) and Gröening (2004). Reference materials are the basis for accuracy across many different types of measurement, not only the mass spectrometry, and there is a large body of literature concerned with the certification and testing of reference materials.
Sources: en.wikipedia.org
On January 4, 2008, the results of a mitochondrial DNA test, comparing the child's DNA with that of his potential grandmother, Clara de Rojas, were revealed by the Colombian government. It was reported that there was a very high probability that the boy was indeed part of the Rojas family. The same day, FARC released a communique in which they admitted that Emmanuel had been taken to Bogotá and "left in the care of honest persons" for safety reasons until a humanitarian exchange took place. The group accused President Uribe of "kidnapping" the child to sabotage his liberation. However, on January 10, 2008, FARC released Rojas and Gonzalez through a humanitarian commission headed by the International Committee of the Red Cross. On January 13, 2008, Venezuelan President Hugo Chávez stated his disapproval with the FARC strategy of armed struggle and kidnapping saying, "I don't agree with kidnapping and I don't agree with armed struggle". He repeated his call for a political solution and an end to the war in March and June 2008: "The guerrilla war is history...At this moment in Latin America, an armed guerrilla movement is out of place". In February 2008, FARC released four other political hostages "as a gesture of goodwill" toward Chávez, who had brokered the deal and sent Venezuelan helicopters with Red Cross logos into the Colombian jungle to pick up the freed hostages. On March 1, 2008, the Colombian armed forces launched a military operation 1.8 kilometres into Ecuador on a FARC position, killing 24, including Raúl Reyes, member of the FARC Central High Command.
==== Stages of genital development ==== The first stage occurs roughly four weeks before the spider's final molt. Unlike adult males, young males possess a broad tarsus that does not appear to consist of any internal structures or appendages. Their pedipalps are greatly bent at a joint connecting the between the tibia and patella. The testes at this point in the young male's life appear very similar to those of the adult males both in terms of physical structure and presence of all stages of spermatogenesis. This spermatogenesis takes place in cysts which contain spermatids. During this time, there is very little observable secretory activity in the testes. In a similar manner to the adult genital system, the vas deferens in young males is connected to the distal, thin part of the testis. The distal portion of the vas deferens is incredibly narrow and is not characterized by the presence of spermatozoa or other secretions. On the other hand, the proximal region consists of a thick epithelium and intricate luminal region containing spermatozoa. The second stage of development is observed two weeks prior the spider's final molt. At this point, the pedipalps of the spider are only partially bent, and the internal structures of the tarsus can be seen. The testes are dimensionally very similar to those of subadult stage one males and adult males. The distal portion of the vas deferens becomes thinner and twists in a tube-like shape. Spermatozoa and other secretions are extensively present in proximal portion of the vas deferens.
Due to the wide array of options in the seafood marketplace, seafood is far more susceptible to mislabeling than terrestrial food. There are more than 1,700 species of seafood in the United States' consumer marketplace, 80–90% of which are imported and less than 1% of which are tested for fraud. However, more recent research into seafood imports and consumption patterns among consumers in the United States suggests that 35%–38% of seafood products are of domestic origin. consumption suggests Estimates of mislabelled seafood in the United States range from 33% in general up to 86% for particular species. Byzantine supply chains, frequent bycatch, brand naming, species substitution, and inaccurate ecolabels all contribute to confusion for the consumer. A 2013 study by Oceana found that one third of seafood sampled from the United States was incorrectly labeled. Snapper and tuna were particularly susceptible to mislabelling, and seafood substitution was the most common type of fraud. Another type of mislabelling is short-weighting, where practices such as overglasing or soaking can misleadingly increase the apparent weight of the fish. For supermarket shoppers, many seafood products are unrecognisable fillets. Without sophisticated DNA testing, there is no foolproof method to identify a fish species without their head, skin, and fins. This creates easy opportunities to substitute cheap products for expensive ones, a form of economic fraud. Beyond financial concerns, significant health risks arise from hidden pollutants and marine toxins in an already fraught marketplace.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.